Phase 2 Trial of BCNU [carmustine] Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2013
At a glance
- Drugs Benzylguanine (Primary) ; Carmustine (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 26 Mar 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 27 Sep 2005 New trial record.